Table 1.

Stages of CKD with prevalence in the US (NHANES 1999 to 2000) and stage specific recommendations for detection, evaluation and management (NKF-K/DOQI)a

Stage of CKDDescriptionGFR (ml/min per 1.73 m2)Detection, Evaluation, and ManagementUS Prevalence in 2000b (%; n in thousands)
1Kidney damage with normal or increased GFR>90Diagnosis and treatment, treatment of comorbid conditions, slowing progression, CVD risk reduction2.8; 5600
2Kidney damage with mild decreased GFR60 to 89Estimate progression2.8; 5700
3Moderate decreased GFR30 to 59Evaluating and treating complications3.7; 7400
4Severe decreased GFR15 to 29Referral to nephrologist and consideration for kidney replacement therapy0.1; 300
5Kidney failure<15Kidney replacement therapy (if uremia present)0.2; 300c
  • a CKD, chronic kidney disease; CVD, cardiovascular disease; NHANES, National Health and Nutrition Examination Survey; NKF-K/DOQI, National Kidney Foundation Kidney Disease Outcomes Quality Initiative.

  • b Kidney damage defined as persistent albuminuria on two occasions (5).

  • c Prevalence of stage 5 is from the US Renal Data System for the number of patients who are on dialysis therapy. This is an underestimation because it does not include the additional unknown number individuals who have kidney failure and are not receiving treatment (17).